Obagi Medical Products to Present at The Canaccord Genuity`s Medical Technology and Diagnostics Forum Conference

Wed Nov 28, 2012 4:33pm EST

* Reuters is not responsible for the content in this press release.

Obagi Medical Products to Present at The Canaccord Genuity’s Medical Technology and Diagnostics Forum Conference

Obagi Medical Products, Inc. (NASDAQ: OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced that President and Chief Executive Officer Albert Hummel will present a corporate overview at The Canaccord Genuity’s Medical Technology and Diagnostics Forum Conference, at Le Parker Meridien Hotel, New York. Obagi Medical’s presentation will take place at 3:00 p.m. (EST) on Tuesday, December 4th.

A live webcast of the presentations will be available via the Internet by visiting the Investor Relations section of the Company’s web site at www.obagi.com. Archived presentations will be available on the web site for 30 days.

About Obagi Medical Products, Inc.

Obagi Medical Products is a specialty pharmaceutical company that develops, markets and sells, and is a leading provider of, proprietary topical aesthetic and therapeutic prescription-strength skin care systems in the physician-dispensed market. Using its Penetrating Therapeutics™ technologies, Obagi Medical’s products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, rosacea, and soft tissue deficits, such as fine lines and wrinkles. Obagi Medical’s portfolio, which includes cosmetic, over-the-counter and prescription products, including 4% hydroquinone, is sold and promoted only through physician offices and requires education by a physician on proper use. Obagi’s skin care products include: Obagi Nu-Derm®, Obagi-C® Rx (a prescription-strength vitamin C and hydroquinone system), Obagi® Professional-C (a line of highly stable vitamin C serums), Obagi Condition &Enhance® for use with cosmetic procedures to enhance patient outcomes and satisfaction, Obagi ELASTIderm® Eye Treatments and Obagi CLENZIderm® M.D. acne therapeutic systems, a formulation of Obagi CLENZIderm M.D. Systems for normal to dry skin, and Obagi ELASTIderm Décolletage System, Obagi Rosaclear® System, Obagi ELASTILash® Eyelash Solution, Obagi Blue Peel RADIANCE®, Nu-Derm® Sun Shield SPF 50 and Nu-Derm® Hydrate. Visit http://www.obagi.com for information.

Penetrating Therapeutics is a trademark, and Obagi, the Obagi logo, Blue Peel RADIANCE, Condition & Enhance, ELASTIderm, ELASTILash, Nu-Derm, Obagi-C, Obagi CLENZIderm and Rosaclear are registered trademarks, of Obagi Medical Products, Inc. and/or its affiliates in the United States and certain other countries.

Obagi Medical Products, Inc.
Preston Romm, 562-628-1007
CFO, EVP of Finance, Operations and Administration
or
Mark Taylor, 562-628-1007
SVP, Corporate Development and Investor Relations

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.